Government ❯Regulation ❯FDA ❯Drug Approval

Patient Safety

FDA Investigates Fatal Liver Failures Linked to Sarepta’s Elevidys Therapy

Two teenage deaths within 90 days of infusion prompted Sarepta to suspend shipments to non-ambulatory patients.

FDA Encourages Lower Doses in Cancer Drug Testing